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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.024Nucleus accumbens-associated protein 1 (NAC1), encoded by the NACC1 gene, is a transcription co-
regulator that plays a multifaceted role in promoting tumorigenesis. However, the NAC1-regulated
transcriptome has not been comprehensively deﬁned. In this study, we compared the global gene
expression proﬁles of NAC1-overexpressing SKOV3 ovarian cancer cells and NAC1-knockdown SKOV3
cells. We found that NAC1 knockdown was associated with up-regulation of apoptotic genes and down-
regulation of genes involved in cell movement, proliferation, Notch signaling, and epithelial-
mesenchymal transition. Among NAC1-regulated genes, FOXQ1 was further characterized because it is
involved in cell motility and epithelial-mesenchymal transition. NAC1 knockdown decreased FOXQ1
expression and promoter activity. Similarly, inactivation of NAC1 by expression of a dominant-negative
construct of NAC1 suppressed FOXQ1 expression. Ectopic expression of NAC1 in NACC1 null cells induced
FOXQ1 expression. NAC1 knockdown resulted in decreased cell motility and invasion, whereas consti-
tutive expression of FOXQ1 rescued motility in cells after NAC1 silencing. Moreover, in silico analysis
revealed a signiﬁcant coeup-regulation of NAC1 and FOXQ1 in ovarian carcinoma tissues. On the basis
of transcription proﬁling, we report a group of NAC1-regulated genes that may participate in multiple
cancer-related pathways. We further demonstrate that NAC1 is essential and sufﬁcient for activation of
FOXQ1 transcription and that the role of NAC1 in cell motility is mediated, at least in part, by FOXQ1.
(Am J Pathol 2014, 184: 133e140; http://dx.doi.org/10.1016/j.ajpath.2013.09.024)Supported byNIH/National Cancer Institute grantsCA103937,CA148826,
and U24CA160036 (I.S.).
A.L.H. is a fellow of Coordenação de Aperfeiçoamento de Pessoal deNível
Superior (CAPES; process No. 10417/12-5).Nucleus accumbens-associated protein 1 (NAC1) is a mem-
ber of the bric-a-bracetramtrackebroad (BTB) family of
proteins that functions as a transcriptional co-regulator.
However, unlike other BTB family proteins, NAC1 lacks a
DNA-binding domain. Therefore, NAC1 is thought to form a
complex with other DNA-binding co-factors to form a
higher-order transcription complex.1 NAC1 participates in
various biological processes, including maintenance of plu-
ripotency in embryonic stem cells,2 regulation of acute psy-
chomotor stimulant responses in mice,3 control of bony
patterning in murine vertebral column,4 and promotion of
tumor development.5 On the basis of analysis of The Cancer
Genome Atlas (TCGA) ovarian cancer data, we identiﬁed
NACC1, the gene encoding NAC1, as one of the most sig-
niﬁcant genes that shows a positive correlation between DNA
and RNA copy number in human cancers,6 suggesting that
NAC1 plays a driver role in cancer development. In fact,stigative Pathology.
.increased expression of NAC1 was found to be associated
with disease aggressiveness, development of chemoresistance,
and tumor recurrence in several types of human cancer,
including ovarian, endometrial, and cervical carcinomas.5,7e14
Experimentally, abundant NAC1 protein is essential for
migration and motility of cancer cells,13,15 maintenance of cell
survival,5,9 prevention of cell senescence,16 and activation of
autophagy in the presence of cisplatin through the high-
mobility group B1 pathway.17 Containing a nuclear localiza-
tion signal, NAC1 is predominantly located in the nucleus.18
However, cytosolic NAC1 can also be detected, especially
during mitosis,19 suggesting that NAC1 may be involved in
Table 1 Oligonucleotide Primers Used for qPCR
Primer Sequence
NAC1 F 50-AAGCTGAGGATCTGCTGGAA-30
NAC1 R 50-CCAGACACTGCAGATGGAGA-30
FOXQ1 F 50-CTCAACGACTGCTTCGTCAA-30
FOXQ1 R 50-GTGTACTCGCTGTTGGGGTT-30
NOTCH1 F 50-CCGCAGTTGTGCTCCTGAA-30
NOTCH1 R 50-ACCTTGGCGGTCTCGTAGCT-30
FOXA2 F 50-TGTTGCTCACGGAGGAGTAG-30
FOXA2 R 50-TTAAAGTATGCTGGGAGCGG-30
CDKN1A F 50-CATGGGTTCTGACGGACATC-30
CDKN1A R 50-TGCCGAAGTCAGTTCCTTGT-30
Jagged1 F 50-ACTGTCAGGTTGAACGGTGTC-30
Jagged1 R 50-ATCGTGCTGCCTTTCAGTTT-30
IGFBP6 F 50-GCCTGCTTGGGGTTTACTCT-30
IGFBP6 R 50-ATCCGCCCAAGGACGAC-30
DBNL R 50-TTGAGCTCCTCCACCATCTC-30
DBNL F 50GAGAAGTCCCCGACCGACT-30
NCOA6 F 50-AGTCGCAGTCCTGCTTGTTT-30
NCOA6 R 50-CGATCTTCTCGACCTGCTTC-30
DVL1 F 50-ACGCTCCTTCTCACGGC-30
DVL1 R 50-CGGGCTTTAGCTATGGCAG-30
KBTBD8 F 50-TGTAAGGCCGCTAGTGAACA-30
KBTBD8 R 50-CGATGAAGGACAGTTGACAGA-30
IDH1 F 50-TCCGTCACTTGGTGTGTAGG-30
IDH1 R 50-GGCTTGTGAGTGGATGGGTA-30
SNF2H F 50-ACCTGCTGCTCAGAAGACTCCAACT-30
SNF2H R 50-GTCGGTAATCGCCAACGGATAGTA-30
m-FOXQ1 F 50-AGCGAAGGAACACTTTTGGA-30
m-FOXQ1 R 50-GGAAGACAAGCGAGGAATGA-30
GAPDH F 50-TTGGTATCGTGGAAGGACTC-30
GAPDH R 50-ACAGTCTTCTGGGTGGCAGT-30
Gao et altranscription-independent cellular events. To this end, we
recently have demonstrated that NAC1 interacts with actin
through the conserved BTB domain and that the NAC1-actin
complex is crucial for effective cytokinesis in cancer cells.15
Given the signiﬁcant and diverse roles of NAC1 in cancer
biology, it is important to identify the NAC1-regulated
transcriptome and determine whether any of these tran-
scripts contribute to the pathogenesis of ovarian cancer. In
this study, we used the SKOV3 cell line as the discovery cell
model and compared the transcriptomes of NAC1-expressing
SKOV3 cells and control, NAC1-knockdown SKOV3 cells.
We further investigated the role of a NAC1-regulated gene,
FOXQ1, in mediating cell motility and invasion.
Materials and Methods
Cell Lines and Culture Conditions
Cancer cell lines used in this study, including SKOV3,
OVCAR5, and HeLa, were purchased from the ATCC (Man-
assas, VA). Cells were maintained in RPMI-1640 (Mediatech,
Manassas,VA) supplementedwith5%(v/v) fetal bovine serum
(Cellgro; Mediatech) and penicillin-streptomycin (Invitrogen,
Grand Island, NY). The HeLa N130 tetracycline-controlled
transactivator inducible cell line was described in our previous
study.7 These cells can be induced to express the NAC1 dele-
tion mutant (N130) that contains only the BTB domain, which
disrupts NAC1 function in cells after removal of doxycycline
from the culture medium.7 Primary culture of lung ﬁbroblasts
derived from NAC1 knockout mice was described in our pre-
vious study.14,15 Brieﬂy, lungs were minced and incubated
with 10 mg/mL of collagenase at 37C to isolate single cells.
Primary cultures of mouse ovarian surface epithelial (OSE)
cells were isolated by scraping the ovarian surface followed by
trypsin digestion of the scraped cells. Cells were cultured in
RPMI-1640 supplemented with 10% (v/v) fetal bovine serum
and penicillin-streptomycin.
Plasmid DNA Constructs and Transfection
To generate the FOXQ1 expression vector, we ﬁrst ampliﬁed
the protein-coding sequence of FOXQ1 by PCR (primers:
forward, 50-ATGAAGTTGGAGGTGTTCGT-30; reverse, 50-
AGGCTAGGAGCGTCTCCA-30) and cloned the PCR prod-
uct into the pLentiToV5HisPuro expression vector. TheNAC1
expression plasmid pcDNA6/NAC1-V5 was previously
described.5,7 Two siRNAs that independently target NACC1
andone control siRNA(StealthRNAi siRNANegativeControl
Med GC) were purchased from Invitrogen. The target se-
quences of the NAC1 siRNAs were 50-ACAUGAUGGGU-
GUGGAGCAUGGCUU-30 and 50-CAGCAGAUCCUCAG-
CUUCUGCUACA-30. Transfection of siRNAswas performed
using Lipofectamine RNAiMAX (Invitrogen). The shRNA
plasmid targeting NAC1 (50-GTACACCATGTACAGCA-
TGAT-30) and the control plasmid (pLKO.1-puro vector) were
obtained fromOpenBiosystems (Thermo Scientiﬁc,Waltham,134MA). For the pGL3-FOXQ1promoter construct,we cloned the
potentialFOXQ1promoter region (1368 toþ120 bp) into the
pGL3-basic vector (Promega, Madison, WI).
Microarray Analysis of Gene Expression
SKOV3 cells were treated with either NAC1 shRNA or
control shRNA lentivirus, and cells were harvested 24 or 48
hours after transduction. Total RNA was isolated using the
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), and RNA
samples were hybridized onto the Human HT-12 v3
Expression BeadChip (Illumina, San Diego, CA). By
comparing the global gene expression proﬁles of NAC1
shRNA-treated and control cells, we selected genes with a
false discovery rate (FDR) <0.002 at either time point for
further analysis. Up- and down-regulated genes were deﬁned
by the regulation status at a given time point with the lowest
FDR. Genes with a >1.5-fold change compared with the
control group were further examined by Ingenuity Pathway
Analysis (Ingenuity Systems, Redwood City, CA). This
analysis is based on expected causal relationships between
input genes and biological functions. The expected causal
relationships are derived from the literature compiled in the
Ingenuity Knowledge Base and allow a prediction for each
function based on the direction of change in gene expression.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Identiﬁcation of NAC1-regulated genes.A: qPCRwas performed
to determine the robustness of shRNA-mediated NAC1 knockdown. NAC1
mRNA level was normalized to GAPDH. B: Western blot analysis of NAC1
protein expression after shRNA-mediated NAC1 knockdown. GAPDH was used
as the loading control. C: Genome-wide transcriptional array analysis iden-
tiﬁed genes differentially expressed between SKOV3 cells treated with NAC1
shRNA virus (N24, N48) and control virus (C24, C48) at 24 and 48 hours. A
threshold ratio of 1.5 was used to select candidate NAC1-regulated genes.
Columns represent experimental samples, and rows represent genes. The
expression level of each gene in an individual specimen is shown as a
pseudocolor gradient based on the normalized, relative expression level of
each gene, where red indicates overexpression and blue indicates under-
expression. D: Pathway analysis of genes affected by NAC1 knockdown. A
heat map shows predicted trends of the six most signiﬁcantly associated
categories of biological function. Each square in the heat map represents a
speciﬁc biological function, and related biological functions are grouped into
major categories. The size of the squares reﬂects the log (P value) of the
biological function, with larger size indicating higher statistical signiﬁcance.
The color of the squares is graded from orange to blue, with orange indicating
a positive Z-score (increased biological function predicted) and blue a
negative Z-score. Biological functions for which a direction could not be
predicted based on the current Ingenuity Knowledge Base are shown in gray.
NAC1 in Ovarian CancerqPCR
First-strand cDNA was synthesized using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). Relative transcrip-
tion levels were measured using the CFX96 Real-Time PCR
Detection System (Bio-Rad) and quantiﬁed by ﬂuorescence
intensity of SYBR Green I (Invitrogen) staining. The real-
time quantitative PCR (qPCR) primers used in this study are
listed in Table 1. Averages in the CT of duplicate mea-
surements were obtained. The relative gene expression level
was calculated by the difference in CT between the gene of
interest and the control gene, GAPDH, which was used as
an internal reference for data normalization.
Western Blot Analysis
Protein lysates were suspended in Laemmli buffer, separated
in a 4% to 15% SDS-PAGE Mini-Protean TGX Gel (Bio-
Rad), and transferred to an 0.2-mm Trans-Blot polyvin-
ylidene diﬂuoride membrane (Bio-Rad) using a semidry
transfer apparatus (Bio-Rad). The membrane was incubated
with the appropriate antibodies and then in enhanced
chemiluminescence developing solution (Thermo Scientiﬁc)
for signal development. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as a loading control. The
antibodies used in this study were anti-NAC1,7 anti-FOXQ1
(AV39755; Sigma, St. Louis, MO), anti-GAPDH (G9545;
Sigma), donkey anti-mouse IgG horseradish peroxidase
(715-035-150; Jackson ImmunoResearch, West Grove, PA),
and donkey anti-rabbit IgG horseradish peroxidase (711-
035-152; Jackson ImmunoResearch).
Luciferase Reporter Assay
SKOV3 and HeLa cells were ﬁrst transfected with NAC1-
targeting siRNA or control siRNA. After 24 hours, cells were
transfected with control pGL3 plasmid or the pGL3-FOXQ1
promoter ﬁreﬂy luciferase constructs and the pRL-Renilla
reporter plasmid (Promega) using Lipofectamine LTX and
Plus Reagent (Invitrogen). The ﬁreﬂy and Renilla luciferase
activities were measured 24 hours after transfection using a
luminometer (PerkinElmer, Waltham,MA) and the Dual-Glo
luciferase reagent (Promega). Fireﬂy luciferase activity was
normalized to Renilla luciferase activity.
Migration and Invasion Assay
Transwell assays were performed to quantify the migration
and invasion of SKOV3 cells. Uncoated inserts (354578;
BD Biosciences, San Jose, CA) were used for migration
assays, and inserts coated with Matrigel (354480; BD Bio-
sciences) were used for invasion assays. Duplicate wells
were used for each experimental condition. Cells were
seeded on top of the inserts, inserts were cultured overnight
and ﬁxed with 4% formaldehyde and stained with 0.1%
crystal violet, and cells that had migrated or invaded to theThe American Journal of Pathology - ajp.amjpathol.orgunderside of the membrane were visualized. Cells were
counted in ﬁve individual ﬁelds on each insert.
In Silico Analysis of Co-Expression of NAC1 and Its
Target Genes
The Z-scores of mRNA expression data from the TCGA
ovarian cancer study were retrieved from the Cancer Geno-
mics Data Server (CGDS) through the cBioPortal for Cancer135
Figure 2 Validation of NAC1-regulated genes (A, down-regulated; B, up-regulated) by qPCR using two independent siRNAs. qPCR was performed to conﬁrm
the candidate NAC1 target genes identiﬁed by microarray analysis. SKOV3 cells were treated with two different NAC1 siRNAs, and NAC1 knockdown efﬁciency
was validated at both mRNA and protein levels. Relative mRNA levels of candidate genes were determined using GAPDH as a reference gene for data
normalization. All results are presented as means  SD. All except two of the candidate genes could be validated (P < 0.05) by both siRNAs.
Gao et alGenomics (http://www.cbioportal.org, last accessed May 11,
2012), hosted by Memorial-Sloan-Kettering Cancer Center
using the CGDS-R software package version 1.1.19
(http://cran.r-project.org/web/packages/cgdsr/index.html, last
accessed May 11, 2012). Z-scores were available for 489
ovarian high-grade serous carcinomas, whose mRNA ex-
pression data were produced on the same platform (Agilent
Technologies, Santa Clara, CA). The scores were calculated
using tumors diploid for each gene as the reference population,
and individual overexpressed and underexpressed genes were
deﬁned by Z-scores >1.65 or <1.65, respectively. We also
assessed the tendency for co-occurrence of NAC1 and its
potential regulated genes by calculating the odds ratios (ORs).Statistical Analysis
Two-tailed t-tests were used to determine signiﬁcance of
differences between groups. Data are presented as means 
SD. P < 0.05 was considered statistically signiﬁcant. For
co-occurrence tests performed in the TCGA ovarian cancer
data set, we followed the criteria used in cBioPortal for
Cancer Genomics, and two genes were considered to have a
tendency toward co-occurrence if the OR was >1.5. The
signiﬁcance of co-occurrence was further tested using a one-
sided Fisher’s exact test.136Results
Identiﬁcation of NACC1-Regulated Genes in Ovarian
Cancer Cells
To identify the potential NAC1-regulated genes, we per-
formed shRNA-mediated knockdown and microarray analysis
of SKOV3 cells, which overexpress NAC1. Total RNA and
proteins were isolated from the cells 24 and 48 hours after
NACC1 knockdown, and both Western blotting and qPCR
were performed to validate NACC1 knockdown efﬁciency.
As expected, we found signiﬁcant down-regulation of
NACC1 mRNA at both 24 and 48 hours (Figure 1A) and
signiﬁcant inhibition of NAC1 protein expression 48 hours
after NAC1 shRNA treatment (Figure 1B), indicating the
robustness of our knockdown approach. Affymetrix Gene-
Chip microarray experiments were then performed, and spe-
ciﬁc transcriptome alterations were detected in NACC1
knockdown cells compared with control cells. This comparison
revealed signiﬁcant changes (fold change,>1.5; FDR,<0.002)
in expression of 710 genes at the transcript level (Figure 1C and
Supplemental Tables S1 and S2). Nearly 70% (493 of 710) of
these genes were down-regulated as a result of shRNA-
mediated knockdown of NACC1, indicating that expression
of most genes was induced by NAC1. Ingenuity pathway
analysis of these 710 genes demonstrated that genes down-ajp.amjpathol.org - The American Journal of Pathology
Figure 3 NAC1 is both required and sufﬁcient for FOXQ1 expression. A:
Western blot analysis demonstrates a decrease in FOXQ1 protein levels 48 hours
after NAC1 knockdown in both SKOV3 and HeLa cells. GAPDH was used as the
loading control. B: Western blot analysis shows an increase in FOXQ1 protein
levels 48hours after ectopicNAC1expression inNACC1/mouseovarian surface
epithelium. GAPDH was used as a loading control. C: qPCR demonstrates that
FOXQ1 expression was induced 24 hours after transfection of a NAC1 expression
construct intoNACC1/mouseﬁbroblasts.D:ExpressionofN130, the truncated
form of NAC1 comprising only the BTB domain, down-regulates FOXQ1 transcript
level in HeLa cells compared with noninduced cells at different time points.
Figure 4 NAC1 regulates FOXQ1 promoter activity. HeLa or SKOV3 cells
were ﬁrst transfected with two independent NAC1 siRNAs to knock down
NAC1 expression. One day later, the pGL3-FOXQ1 (black bars) promoter
construct or pGL3 control plasmid (white bars) was transfected into the
cells. Luciferase activity was measure 24 hours after transfection of the
promoter construct. FOXQ1 promoter activity in NAC1 siRNA-treated cells is
signiﬁcantly lower than in the control siRNA-treated cells. **P < 0.01.
NAC1 in Ovarian Cancerregulated by NACC1 knockdown were enriched in pathways
related to cell movement, cell and tissue development, and
growth and proliferation, whereas genes up-regulated by
NACC1 knockdown were enriched in the pathway related to
cell death (Figure 1D and Supplemental Tables S3 and S4).
To validate the microarray results, qPCR was performed
using two independent NACC1 siRNAs for 11 genes selected
based on prior knowledge of their involvement in cancer-
associated pathways. All genes were validated by both siR-
NAs (P< 0.05) (Figure 2), with the exception ofNCOA6 and
IDH1, which could be conﬁrmed by only one siRNA. These
genes include those whose transcription was supported by
NACC1, such as FOXQ1 FOXA2, IGFBP6, NOTCH1,
JAGGED1, DBNL, and DVL1 (Figure 2A), and those whose
transcription was repressed by NACC1, including SNF2HThe American Journal of Pathology - ajp.amjpathol.organd IDH1 (Figure 2B). In this study, we further validated
representative members of the Notch pathway by either
NAC1 knockdown or ectopic expression of NAC1 in other
cell lines, including SKOV3TR (a paclitaxel-resistant SKOV3
variant), OVCAR5, and OSE4. Because Notch3 has been
known to play an important role in the pathogenesis of ovarian
high-grade serous carcinoma,20e23 we also included Notch3
in the analysis. As shown in Supplemental Figure S1,NACC1
knockdown resulted in decreased levels of Jagged1 and
Notch3 mRNA expression in both SKOV3TR and OVCAR5
cells, whereas ectopic expression of NAC1 in OSE4 cells led
to increased levels of Jagged1, Notch1, and Notch3 mRNA.
FOXQ1 Expression Is Transcriptionally Regulated by
NAC1
Among the NACC1-regulated genes, FOXQ1 was selected for
further study because of its reported functions in cancer and
stem cell biology.24e26 We ﬁrst determined whether NAC1
was necessary and/or sufﬁcient to regulate FOXQ1 expression.
As shown in Figure 3, bothNACC1 siRNAs inhibited FOXQ1
protein expression (Figure 3A and Supplemental Figure S2),
and ectopic expression of NAC1 in mouse ovarian surface
epithelium and lung ﬁbroblasts established from NACC1/
mice signiﬁcantly increased FOXQ1 expression (Figure 3,137
Figure 5 Ectopic expression of FOXQ1 increases motility of NAC1-
knockdown cells. A: FOXQ1 cDNA tagged with a V5 epitope was cloned into
the pLenti lentiviral vector. SKOV3 cells were transfected with the pLenti/
FOXQ1-V5 or control plasmid. FOXQ1 protein expression was analyzed by
Western blot using an anti-V5 antibody. GAPDH was used as a loading
control. B: NAC1 siRNA- or control siRNA-treated SKOV3 cells were trans-
fected with pLenti/FOXQ1-V5 or control plasmid, and migration (B) and
invasion (C) were measured in Transwell assays. Compared with control cells
(siCTRL), NAC1 siRNA-treated cells have a reduced capacity to migrate or
invade in both pLenti- and pLenti/FOXQ1-V5 transfected groups (P< 0.001).
Ectopic FOXQ1 expression increases the migration and invasiveness of NAC1-
knockdown cells. For each group, data were normalized to control siRNA-
treated samples. The error bars represent one SD. *P < 0.05, **P < 0.01.
Gao et alB and C, and Supplemental Figure S3). Because BTB
domainemediated protein dimerization is known to contribute
to the biological functions of NAC1, we tested whether
disruption of NAC1 dimerization by N130 affected FOXQ1
expression.As shown in Figure 3D, induction ofN130 resulted
in signiﬁcant suppression of FOXQ1 transcript levels in HeLa
cells at different time points, particularly at 6 hours after N130
induction. To assess whether NAC1 regulates FOXQ1 tran-
scription through FOXQ1 promoter activity, we performed a
FOXQ1 promoter reporter assay. Reporter plasmid that con-
tained the FOXQ1 promoter sequence was transfected into
NAC1-overexpressingSKOV3andHeLa cells. Suppressionof
NAC1 expression by two different NACC1 siRNAs signiﬁ-
cantly reduced the luciferase activity associated with the
FOXQ1 promoter reporter (Figure 4).
FOXQ1 Mediates NAC1-Induced Cell Motility and
Invasion
Next, we addressed the role of FOXQ1 in mediating the
biological functions of NAC1. Because NAC1 is involved in
cell proliferation, drug resistance, andmigration and invasion,
we investigated whether any of these phenotypes were
mediated byFOXQ1 inNAC1-overexpressing cancer cells. A
rescue assay was performed to determine the salvage effect of
ectopic expression of FOXQ1 in cells with siRNA-mediated
NAC1 knockdown using two independent siRNAs. Our data
demonstrate that ectopic expression of FOXQ1 did not rescue
cell proliferation or restore paclitaxel resistance in NAC1-
knockdown cells (data not shown). However, ectopic
expression of FOXQ1 signiﬁcantly increased cell migration
and invasion compared with control cells without engineered
expression of FOXQ1, suggesting that FOXQ1, at least in
part, mediates cell motility induced by NAC1 (Figure 5).
Correlation of NACC1 and Target Gene Expression in
Ovarian Cancer Tissues
The TCGA ovarian high-grade serous carcinoma data
set allowed us to perform statistical analysis to determine the
co-occurrence of aberrant expression ofNACC1 and its target
genes in 489 ovarian high-grade serous carcinoma tissues. Of
493 genes that were potentially up-regulated and the 217
genes that were potentially down-regulated by NACC1, gene
expression datawere available from the cBioPortal for Cancer
Genomics for 477 up-regulated and 210 down-regulated
genes (Supplemental Tables S5 and S6). Of the 477 poten-
tially up-regulated genes, 125 (26.2%) had a tendency toward
linked up-regulation with NACC1 (OR Z >1.5), and
52 (10.9%) of these associations were statistically signiﬁcant
(P < 0.05). Notably, there was signiﬁcant co-occurrence of
NACC1 andFOXQ1 up-regulation (ORZ 6,PZ 0.0002). Of
the 210 genes that were potentially down-regulated byNAC1,
67 (31.9%) had a tendency toward co-occurrence with
NACC1 overexpression, and 50 (23.8%) of these associations
were statistically signiﬁcant. The ORs and P values of138co-occurrence with NACC1 up-regulation and down-
regulation for each gene are shown in Supplemental Tables
S5 and S6, respectively, and the pattern of co-regulation for
representative genes is shown in Supplemental Figure S4.
Discussion
Evidence is accumulating to indicate a multifaceted role of
NAC1 in cancer pathogenesis, including promotion of cell
survival and proliferation, acquisition of resistance toajp.amjpathol.org - The American Journal of Pathology
NAC1 in Ovarian Cancerchemotherapeutic agents, enhancement of cell motility, and
autophagy. These multiple functions are thought to be
related to the transcriptional regulatory activity of NAC1.
Although NAC1 lacks a DNA-binding domain, it may
actively participate in transcriptional regulation by inter-
acting with a speciﬁc transcription complex. On the basis of
comparison of the transcriptomes of NAC1-knockdown and
control SKOV3 ovarian cancer cells, we identiﬁed a set of
genes whose expression levels depend on the NAC1 ex-
pression level. Moreover, we were able to validate NAC1
regulation of representative target genes, conﬁrming the
robustness of the microarray analysis for discovering
NAC1-regulated genes. Interestingly, a substantial number
of NAC1 downstream candidate genes, including FOXQ1,
exhibited a pattern of co-expression with NACC1 in a large
cohort of human ovarian high-grade serous carcinoma tis-
sues. This result further supports the idea that NAC1 may
regulate these target genes at the tissue level.
The current study has suggested a regulatory role of
NAC1 in several well-known cancer-associated pathways,
including those involved in cell proliferation, apoptosis,
Notch signaling, cell motility and invasion, and epithelial-
mesenchymal transition. Among these, potential activation of
Notch signaling by NAC1 is of particular interest. Our current
data indicate that expression of Notch receptor and its ligand
Jagged1 depends on NAC1 in at least one of the cell lines
tested (Figure 2A and Supplemental Figure S1). It is well
established that overexpression of the Notch receptor and
Jagged1 activates Notch signaling, a molecular pathway that
controls cell fate during development and that aberration of
this pathway contributes to cancer development. We have
demonstrated that Jagged1 is the primary Notch ligand in
ovarian cancer and that the Jagged1-Notch interaction con-
stitutes a juxtacrine loop, promoting proliferation and
dissemination of ovarian cancer cells within the intraperito-
neal cavity.23 Inactivation of the Notch pathway results in
growth inhibition and induction of apoptosis in ovarian cancer
cells, suggesting that targeting the Notch signaling pathway
may represent a new therapeutic approach for ovarian can-
cer.21,22,27 Thus, our results indicating that NAC1 is necessary
for maintaining the expression of the Notch receptor and
Jagged1 in SKOV3 or OVCAR5 ovarian cancer cells and that
NAC1 expression is sufﬁcient to up-regulate Notch receptor
and Jagged1 in OSE4 cells provide new insight into the
complex regulatory network underlying Notch signaling.
In this study, we found that expression of several members of
the FOX family, including FOXQ1, FOXA2, FOXJ2, and
FOXS1, decreases after NAC1 knockdown (Supplemental
Table S1), suggesting that their expression depends on NAC1.
Several members of the FOX gene family are known to have a
plethora of biological functions, including embryonic devel-
opment and cell cycle progression.28,29 In this study, we
demonstrate that NAC1 is not only essential but also sufﬁcient
to maintain FOXQ1 expression. Because FOXQ1 has been
established as an important gene in epithelial-mesenchymal
transition,24e26 and its up-regulation is associated with poorThe American Journal of Pathology - ajp.amjpathol.orgprognosis in colorectal, breast, and nonesmall cell lung carci-
nomas, NAC1may also contribute to epithelial-mesenchymal
transition and aggressiveness of disease through up-
regulation of FOXQ1. To this end, we have recently
demonstrated that ovarian carcinoma cells express a higher
level of FOXQ1 than normal epithelial cells.26 Silencing of
FOXQ1 expression using a shRNA-mediated knockdown
approach altered gene expression of several cell cycle reg-
ulators, leading to suppressed cell proliferation and reduced
cell motility and invasion. Consistent with previous reports,
FOXQ1 up-regulated epithelial markers and down-
regulated mesenchymal cell markers, indicating that
FOXQ1 is involved in epithelial-mesenchymal transition in
ovarian cancer cells. Of note, in the present study, we found
that NAC1 dimerization is required to sustain FOXQ1
expression, suggesting inhibition of NAC1 dimerization as
a possible strategy to suppress FOXQ1 expression.
This study also raises several important questions to be further
addressed. For example, it is important to determinewhich other
NAC1-regulated genes mediate the key biological functions of
NAC1, such as resistance to chemotherapeutic agents and plu-
ripotency of stem cells. It is plausible that a subset of NAC1-
regulated genes cooperates to mediate unique functions of
NAC1. As evidenced by our data for FOXQ1 (Figure 5),
although ectopic expression of FOXQ1 abated the suppressive
effect ofNAC1knockdownoncellularmotility, the rescue effect
was modest at best, suggesting that other NAC1 downstream
genes may be also involved in this phenotype. In fact, pathway
analysis demonstrated that several NAC1-regulated genes,
including IGFBP6,30 CXCL1,31 DNBL,32 ROCK2,33 and
ADAMTS1,34 are also involved in cellular motility and invasion.
In conclusion, we identiﬁed the NAC1-regulated genes in
ovarian cancer cells and found a signiﬁcant correlation be-
tween the expression levels of NAC1 and its downstream
target genes in human cancer tissues. This compendium of
NAC1 targets is fundamental for future studies aimed at
delineating the biological roles of NAC1 in the pathogenesis
of tumor development. The fact that NAC1 regulates ex-
pression of multiple tumor-associated genes and pathways
indicates that NAC1 may serve as one of the master mo-
lecular switches in promoting oncogenesis in human cancer.
Targeting the NAC1 pathway by, for example, using small
molecule compounds to prevent NAC1 dimerization may
have translational implications in designing new therapeu-
tics to treat cancers that exhibit NAC1 up-regulation.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.09.024.
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